Search

Objectives: This study was aimed to evaluate the frequency of fibromyalgianess, fibromyalgia syndrome (FS) and widespread pain in patients with Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) and their relationship with clinical and demographic parameters. Patients and Methods: This cross-sectional multicenter trial was performed in 14 centers across Türkiye. 661 patients (342 RA, 319 AS) have been recruited for the study. In these cohorts those who did not meet the criteria for FS and had widespread pain (widespread pain index≥7) were evaluated as a separate group. Clinical status and demographic parameters of patients in both cohorts were evaluated as well as the evaluations of RA and AS patients with widespread pain (widespread pain index≥7) and RA and AS patients with FS groups. In addition, correlations between Polysymptomatic Distress Scale (PSD) scores and visual analogue scale (VAS), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Disease Activity Score using 28 joint counts (DAS 28) for RA patients and VAS, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) for AS patients were analyzed. Results: Frequencies of patients with FS and patients who had PSD scores≥12 were 34.1% and 44.4% in all RA patients respectively. Moreover, FS and PSD scores ≥12 were found as 29.2% and 36.9% in all AS patients respectively. PSD scores of RA patients with FS were higher than all RA and RA with widespread pain patients’. SDAI and CDAI scores of RA patients with FSwere higher than all RA and RA with widespread pain patients’as well. Similarly,PSD scores of AS patients with FS were higher than all AS and AS with widespread pain patients’. ASDAS-ESR and BASDAI scores of AS patients with FS were found higher than all AS and AS with widespread pain patients’. Conclusion: Disease activity scores including pain in RA and AS patients’ were seemed higher in the presence of FS or fibromyalgianess. It may be related to clinical parameters, but cohort studies with long-term follow-up are needed in order to reveal causality. Additionally, in order to reduce overtreatment, coexistence of fibromyalgianess should be kept in mind in patients who had inflammatory diseases like RA and AS especially with intractable widespread pain.

Objectives: This study aims to evaluate the effectivity of Familial Mediterranean Fever Quality of Life (FMF-QoL) Scale for the measurement of QoL in patients with FMF and to perform correlations between related clinical variables in Turkish patients. Patients and methods: This multicenter prospective study performed between December 2017 and November 2018 included 974 FMF patients (334 males, 640 females; median age: 35; range, 26 to 45 years). Sociodemographic characteristics and clinical features were recorded. All participants were asked to complete the FMF-QoL Scale, Short Form-36 (SF-36), Hospital Anxiety and Depression Scale (HADS), Health Assessment Questionnaire (HAQ), and Functional Assessment of Chronic Illness Therapy (FACIT) Scale. Results: The median FMF-QoL Scale score was 26. Higher FMF-QoL Scale scores were shown to be related to female sex, illiteracy or primary education, monthly low-income (US$20 years), a higher number of attacks per month (>1/month), and severe disease. FMF-QoL Scale scores were correlated negatively with subscales of SF-36, and positively with HADS-anxiety and HADS-depression scores, HAQ and FACIT. Conclusion: Female sex, smoking, lower educational status, more severe disease, fatigue, and functional impairment were associated with poor QoL. FMF-QoL Scale was noted as a valid and simple patient-reported outcome instrument and correlated with the SF-36 scale.

Aim Osteoarthritis (OA) of the knee is one of the major causes of joint dysfunction and physically disabling conditions in the older population. The risk factors for the development of knee OA are very diverse. We aimed to determine the frequency of joint hypermobility in patients with knee OA. Methods Five hundred and three patients (402 female and 101 male) with bilateral knee OA were enrolled in five different clinics from three regions of Turkey. In this study, joint hypermobility was evaluated in the participants by using the Beighton scoring system and a Beighton score of at least 4 was considered as joint hypermobility. Radiological scoring was performed according to Kellgren and Lawrence. Results The percentages of generalized joint hypermobility were determined as 21.5% in all of the patients, 23.9% in female patients and 11.9% in male patients. The percentage of hypermobility (67.9%) was found to be highest in patients with knee OA aged between 22–30 years as against other age groups. Highest hypermobility percentage was found as 73.9% (17/23) in female patients and as 40% (2/5) in male patients between 22–30 years. The hypermobility of knee was found to have the highest frequency in patients aged between 22–40 years as compared to other joint regions and also to be second-highest frequency in all patients aged between 41–92 years. As a result, generalized joint hypermobility was determined to be of high frequency in patients with knee OA. Furthermore, we have seen that knee mobility was established to be of considerably high frequency in patients with knee OA. Conclusions This study showed generalized joint hypermobility and knee hypermobility may be associated with knee OA. According to the results of this study, we can suggest that generalized joint hypermobility and also knee hypermobility may increase the risk of knee OA. According to this study, it should be considered that knee OA will develop in individuals who have generalized joint hypermobility and these individuals should be educated from this point before OA it occurs.

INTRODUCTION: In this study, we aimed to investigate dermatological side effects DSE seen in patients with rheumatic diseases taking TNF-α blocker. METHODS: A total number of 103 patients with chronic inflammatory rheumatic diseases on TNF-α blocker treatment were included into the study. All cutaneous leisons in patients were recorded as before and after TNF-α blocker treatment. TNF-α blockers-related DSE were grouped as infectious and non-infectious. The demographic and clinical characteristics of patients with DSE examined. In addition, demographic and clinical characteristics of the patients with infectious and non-infectious DSE were compared.RESULTS: 103 patients 40 female between the age of 18-74 were included into the study. Totally 63 cutaneous leisons occured during TNF-α blocker treatment were determined in 50 % 48.54 patients. 25 onychomycosis, 7 psoriasis, 1 diskoid lupus eritematozus, 1 basal cell carcinoma, 1 palmoplantar pustulosis, 28 other cutaneous lesions. 36 72% of patients with DSE had infectious skin lesions. 14 38% of patients with DSE had non-infectious skin. DSE were significantly higher in patients receiving concomitant methotrexate MTX . İnfectious DSE were significantly higher than non infectious DSE in patients receiving concomitant MTX. There was no relationship between DSE with the type of TNF-α blocker and rheumatic diseases.DISCUSSION AND CONCLUSION: As a result, DSE ranging from onychomycosis to malignancies can be seen during be seen during TNF-α blocker therapy. Monitoring for DSE of the patients receiving TNF-α blocker treatment is important for early diagnosis and treatment., GİRİŞ ve AMAÇ: Biz bu çalışmada, romatizmal hastalığı nedeniyle TNF-α bloker tedavisi alan hastalarda, tedavi süresince gelişmiş olan dermatolojik yan etkileri DYE saptamayı amaçladık.YÖNTEM ve GEREÇLER: Romatizmal hastalığı nedeniyle TNF-α bloker tedavisi alan 103 hasta çalışmaya dahil edildi. Hastalarda saptanan tüm cilt lezyonları, tedavi öncesi ve sonrası olarak kaydedildi. TNF-α bloker tedavisi sürecinde gelişen dermatolojik lezyonlar enfeksiyöz ve non-enfeksiyöz olarak gruplandırıldı. Tedavi sürecinde DYE geliştiren hastaların demografik ve kinik özellikleri incelendi. Ayrıca enfeksiyöz ve non-enfeksiyöz DYE gelişen hastaların demografik ve kinik özellikleri karşılaştırıldı.BULGULAR: Bu çalışma da yaşları 18-74 arasında değişen 103 hasta 40 kadın değerlendirildi. Toplam 50 % 48,54 hastada TNF-α bloker tedavi sürecinde gelişmiş 63 cilt lezyonu tespit edildi 25 onikomikoz, 7 psoriazis, 1 diskoid lupus eritematozus, 1 basal hücreli karcinom, 1 palmoplantar pustuloz, 28 diğer cilt lezyonu . Anti TNFα tedavi sürecinde DYE gelişmiş 50 hastanın 36 %72 ‘ sında enfeksiyöz, 14 %38 ’ ünde non-enfeksiyöz cilt lezyonları mevcuttu. Eş zamanlı methotrexate MTX kullanan hastalarda DYE anlamlı olarak daha sık bulundu. Bunlar arsında enfeksiyöz DYE’ lerin, non-enfeksiyöz olanlardan anlamlı olarak daha yüksek olduğu görüldü. Hastalığın tanısı ve kullanılan TNF-α bloker ile DYE ‘ ler arasında anlamlı bir fark bulunmadı.TARTIŞMA ve SONUÇ: TNF-α blokerler ile tedavi sürecinde, onikomikoz dan malignitelere kadar değişen yelpazede farklı dermatolojik yan etkiler gelişebilir. Sonuç olarak, TNF-α bloker tedavisi alan hastaların, DYE’ ler açısından takip edilmesi, erken tanı ve tedavi açısından önemlidir.